Conformational Analysis of the DFG-Out Kinase Motif and Biochemical Profiling of Structurally Validated Type II Inhibitors-Reference-Cited by-同舟云学术

Conformational Analysis of the DFG-Out Kinase Motif and Biochemical Profiling of Structurally Validated Type II Inhibitors

Published:2014-12-12 Issue:1 Volume:58 Page:466-479
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Vijayan R. S. K.¹²,He Peng¹²,Modi Vivek³,Duong-Ly Krisna C.⁴,Ma Haiching⁵,Peterson Jeffrey R.⁴,Dunbrack Roland L.³,Levy Ronald M.¹²

Affiliation:

1. Center for Biophysics & Computational Biology and Institute for Computational Molecular Science, Temple University, Philadelphia, Pennsylvania 19122, United States

2. Department of Chemistry, Temple University, Philadelphia, Pennsylvania 19122, United States

3. Developmental Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, United States

4. Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, United States

5. Reaction Biology Corporation, Malvern, Philadelphia, Pennsylvania 19355, United States

Funder

National Institute of General Medical Sciences

Fox Chase Cancer Center

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm501603h

Reference65 articles.

1. The Protein Kinase Complement of the Human Genome

2. CONVERSION OF PHOSPHORYLASE b TO PHOSPHORYLASE a IN MUSCLE EXTRACTS

3. Evolution of protein kinase signaling from yeast to man

4. The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication

5. Crystal Structure of the Catalytic Subunit of Cyclic Adenosine Monophosphate-Dependent Protein Kinase

Cited by 177 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of GNE-6893, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of HPK1;ACS Medicinal Chemistry Letters;2024-09-03

2. Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity;European Journal of Medicinal Chemistry;2024-09

3. Futibatinib (Lytgobi): A Selective Irreversible FGFR1–4 Inhibitor;Chemistry and Pharmacology of Drug Discovery;2024-08-16

4. Evolutionary sequence and structural basis for the distinct conformational landscapes of Tyr and Ser/Thr kinases;Nature Communications;2024-08-02

5. A comprehensive exploration of the druggable conformational space of protein kinases using AI-predicted structures;PLOS Computational Biology;2024-07-24